Passage Bio (PASG)
(Real Time Quote from BATS)
$0.62 USD
+0.02 (3.32%)
Updated Oct 4, 2024 12:52 PM ET
3-Hold of 5 3
D Value B Growth B Momentum B VGM
Income Statements
Fiscal Year end for Passage Bio, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 108 | 138 | 186 | 113 | 37 |
Income After Depreciation & Amortization | -108 | -138 | -186 | -113 | -37 |
Non-Operating Income | 6 | 2 | 0 | 1 | -8 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -102 | -136 | -185 | -112 | -46 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -102 | -136 | -185 | -112 | -46 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -102 | -136 | -185 | -112 | -46 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -107 | -134 | -181 | -111 | -37 |
Depreciation & Amortization (Cash Flow) | 2 | 4 | 4 | 1 | 0 |
Income After Depreciation & Amortization | -108 | -138 | -186 | -113 | -37 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 54.74 | 54.43 | 53.34 | 38.62 | NA |
Diluted EPS Before Non-Recurring Items | -1.86 | -2.50 | -3.33 | -2.91 | NA |
Diluted Net EPS (GAAP) | -1.86 | -2.50 | -3.48 | -2.91 | NA |
Fiscal Year end for Passage Bio, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 17.38 | 18.06 | 18.45 | 28.67 | 25.38 |
Income After SG&A, R&D, and Dept/Amort Expenses | -17.38 | -18.06 | -18.45 | -28.67 | -25.38 |
Non-Operating Income | 1.39 | 1.34 | 4.77 | 1.56 | 1.53 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -15.99 | -16.71 | -16.76 | -27.11 | -23.86 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -15.99 | -16.71 | -16.76 | -27.11 | -23.86 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -15.99 | -16.71 | -16.76 | -27.11 | -23.86 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 61.68 | 56.30 | 54.98 | 54.79 | 54.68 |
Diluted EPS Before Non-Recurring Items | -0.26 | -0.30 | -0.30 | -0.49 | -0.44 |
Diluted Net EPS (GAAP) | -0.26 | -0.30 | -0.30 | -0.49 | -0.44 |